Background and objectives: Cognitive impairment is common among persons with ESRD, but the underlying mechanisms are unknown. This study evaluated the prevalence of cognitive impairment and association with modifiable ESRD-and dialysis-associated factors in a large group of hemodialysis patients.
C ognitive impairment is common among persons with ESRD and is associated with poor outcomes (1-3), but its underlying mechanisms remain poorly understood. As a result, few evidence-based strategies exist for treating this serious morbidity. Uncontrolled studies have reported improvements in cognitive function after kidney transplantation, and more recently, after conversion from conventional to nocturnal hemodialysis (4 -6) , suggesting that modifiable factors associated with ESRD and/or its treatment may be implicated in the pathogenesis of this disorder.
Several ESRD-and dialysis-associated factors such as retention of uremic solutes, hypertension, hemodynamic instability during dialysis, and anemia may be favorably modified by more frequent hemodialysis schedules. Several of these conditions have also been implicated in the pathogenesis of cognitive impairment. For example, in the National Cooperative Dialysis Study, higher levels of urea clearance were correlated with better cognitive performance (7) . In addition, cardiovascular and hemodynamic factors (hypertension, and at the other extreme, intradialytic hypotension) may lead to stroke or cerebral ischemia and contribute to cognitive impairment in patients with ESRD (8, 9) . Anemia has also been associated with poor cognitive function and dementia (1, 10) . Central nervous system (CNS)-active medications are prescribed for various ESRD-associated conditions, but the frequency of their use and their effects on cognitive function in patients with ESRD have not been carefully studied.
The evaluation of cognitive function involves the assessment of a range of cognitive domains, such as memory, language, attention, and executive function (i.e., the cognitive skill necessary for planning and sequencing tasks). Cognitive impairment that is caused by or associated with different neurologic or systemic illnesses may be characterized by impairments in specific cognitive domains, especially in early stages. For example, memory impairment is an early feature of Alzheimer's dementia, whereas vascular causes of cognitive impairment are frequently associated with diminished executive function (11) . A few studies have suggested that impaired executive function is common among patients with ESRD (2, 12) , but its correlates are unknown.
The Frequent Hemodialysis Network (FHN) trials consist of two randomized trials comparing more frequent hemodialysis schedules with conventional thrice-weekly hemodialysis schedules for patients with ESRD. These trials provide a unique opportunity to assess the relations among cognitive impairment, ESRD, ESRD-associated factors, and the frequency of hemodialysis. The goals of the analyses presented here were to assess the prevalence and correlates of impaired global cognitive function and impaired executive function with modifiable ESRD-and dialysis-associated conditions in a large group of hemodialysis patients participating in the FHN trials.
Materials and Methods

Subjects
The design, recruitment, and measurements of the FHN trials have been previously published (13) . Briefly, we recruited subjects with ESRD requiring maintenance hemodialysis from clinical sites in the United States and Canada for one of two trials: (1) a trial of 6-timesper-week hemodialysis versus 3-times-per-week in-center hemodialysis (daily trial), or (2) a trial of 6-times-per-week home nocturnal dialysis versus 3-times-per-week in-center or home hemodialysis (nocturnal trial). Major exclusion criteria included age Ͻ13 (daily) or Ͻ18 (nocturnal) years, inability to achieve a mean estimated Kt/V urea Ն 1.0 on two occasions, life expectancy Ͻ6 months, medical need for hemodialysis Ͼ3 times per week, residual urea clearance Ͼ3 ml/min (daily), history of poor adherence to hemodialysis, medical conditions preventing cardiac magnetic resonance imaging, inability to communicate in English or Spanish, and anticipated kidney transplantation or relocation within the next 14 months. Institutional review boards at each clinical center reviewed the study, and all subjects signed informed consent. For these analyses, we included individuals who were enrolled in either trial and completed baseline cognitive function testing, whether or not they were randomized. We excluded individuals Ͻ21 years of age and those missing baseline cognitive function scores, resulting in an analytic cohort of 383 subjects (Figure 1 ).
Explanatory Variables and Covariates
At enrollment, before randomization, we recorded demographic and clinical characteristics, anthropometric measures, hemodialysis treatment parameters, laboratory measures, and medication use for each study subject. Comorbid conditions were assessed using the modified Charlson Comorbidity Index (14) . Depressive symptoms were defined as a score Ն15 on the Beck Depression Inventory (15, 16) . Quality of life was assessed with the SF-36 Physical Health Component and Mental Health Component scales (17) . Laboratory variables were measured predialysis at laboratories affiliated with each clinical center.
We selected a priori five main categories of predictor variables: (1) urea clearance, (2) nutritional markers, (3) hemodynamic markers, (4) anemia, and (5) CNS-active medications. We characterized the weekly clearance of urea using standard Kt/V (stdKt/V urea ), calculated as the average stdKt/V urea from two baseline kinetic modeling sessions, as described previously (18) . We selected four nutritional markers: (1) normalized protein catabolic rate (enPCR); (2) body mass index (BMI); (3) body composition as estimated by bioelectrical impedence analysis (BIA), herein reflected by the phase angle; and (4) serum albumin concentration. enPCR was calculated from blood urea nitrogen measurements collected at baseline kinetic modeling sessions. Body weight was measured immediately after a hemodialysis session. BIA was performed with the subject recumbent, immediately before a midweek hemodialysis treatment. Narrower (lower) phase angles derived from BIA have been used to indicate malnutrition in ESRD patients (19) . We selected three hemodynamic markers: (1) predialysis BP; (2) ultrafiltration volume (expressed per kilogram dry weight); and (3) history of intradialytic hypotension, defined as receipt of intravenous saline during a hemodialysis session in the prior week. Use of the following CNS-active medications was recorded for each subject: benzodiazepines, antidepressants, anticonvulsants, H1-receptor antagonists, and opioids.
Dependent Variables
We assessed cognitive function with two cognitive tests at enrollment by trained study coordinators in English or Spanish, as appropriate. The Modified Mini-Mental State Exam (3MS) is a test of global cognitive function that includes an assessment of orientation, attention, calculation, language, and short-term memory (20) . Scores range from 0 to 100, and lower scores indicate poorer cognitive function. The Trailmaking B (Trails B) test is a timed test of executive function, a cognitive domain not assessed with the 3MS (21) . Higher scores on the Trails B indicate poorer executive function. On the basis of pilot testing, we extended the test ceiling from 300 seconds (the conventional text maximum) to 600 seconds. We defined global cognitive impairment as a 3MS score Ͻ80 and impaired executive function as a Trails B score of Ն300 seconds, consistent with prior studies (12) . Tests were administered mid-week predialysis unless this was infeasible (e.g., subjects on dialysis shifts starting before 6:00 a.m.), in which case tests were administered on a nondialysis day. 
Statistical Analyses
Baseline characteristics of the sample were stratified according to trial and randomization status and characterized using mean (Ϯ SD), medians (interquartile range [IQR]) or frequencies (%), as appropriate. We first graphically evaluated the association between each explanatory variable and cognitive test score. Variables that had nonlinear associations with cognitive function scores were divided into categories on the basis of conventionally defined cut points (BMI, phosphorus), or into quartiles if defined cut points did not exist (BIA). Next, we determined the association of each explanatory variable with cognitive impairment for each test separately using logistic regression, expressed as an odds ratio (OR) and 95% confidence interval (CI). We determined the unadjusted association and the case-mix-adjusted association of each explanatory variable after adjustment for age, race, primary language (English versus other), education, and stroke. We repeated the analyses after excluding individuals whose primary language was not English. In separate analyses, individuals with a history of stroke were excluded to assess whether the dominant effect of stroke on cognitive function masked more subtle influences of ESRD-and dialysis-associated factors. We also conducted sensitivity analyses using a less stringent 3MS cut point for those with high school education (3MS Ͻ 88) and separately after adjustment for quality-of-life scores.
Finally, we developed multivariable models for each cognitive impairment outcome and adjusted for age, race, primary language, education, stroke, and included other variables significant at the P Ͻ 0.1 level in case-mix-adjusted analyses with stepwise backward selection using a significance value Ͻ0.025 for inclusion into the final model (P Ͻ 0.05, adjusted for analyses incorporating two dependent variables-3MS and Trails B). Before developing the multivariable model, missing values were multiply imputed while incorporating auxiliary variables reflecting factors for baseline dropout (22) . Missing values for education level were assigned a value of "unknown." Standard errors for the multivariable models corrected for the multiple imputation. All analyses were conducted using SAS version 9.1 (Cary, NC).
Results
There were 383 subjects included in the analytic cohort, with 286 subjects enrolled in the daily trial and 97 subjects enrolled in the nocturnal trial. Subjects who were excluded because of missing cognitive scores had a smaller median ESRD vintage but were otherwise similar to the analytic cohort. Subjects included in the analytic cohort had a mean age of 51.6 Ϯ 13.3 years and 62% were men, 42% were white, and 42% had diabetes ( Table 1 ). The median ESRD vintage was 2.6 (IQR 1.0 to 6.2) years. Primary reasons for nonrandomization included significant residual kidney function (daily), contraindication to cardiac magnetic resonance imaging, and inability or unwillingness to adhere with the study protocol. The distribution of selected laboratory measurements and treatment parameters is shown in Table 2 .
The median score on the 3MS was 90 (IQR 83 to 94), and the median score on the Trails B was 130 seconds (IQR 79 to 396 seconds). Sixty-one subjects (16%) had a 3MS score Ͻ80 and 110 participants (29%) had a Trails B score Ն300 seconds, indicating marked impairment on each of the respective tests. Thirty-six subjects (9%) had impairment on both cognitive tests, 25 subjects (7%) had global cognitive impairment without impaired executive function, and 74 subjects (19%) had isolated impairment of executive function (Figure 2 ). The percentage of subjects with impairment on each test increased with age, reaching 31% to 61% for those age 70 to 85 years ( Figure 3 ).
Impairment in Global Cognitive Function (3MS)
In univariate analyses, older age, primary language other than English, lower educational attainment, and depressive symptoms were significantly associated with a higher odds of global cognitive impairment, whereas participation in the nocturnal trial (versus the daily trial), higher serum phosphorus concentrations, and antidepressant use were significantly associated with a lower odds of global cognitive impairment (Table 3) . After case-mix adjustment, white race was also significantly associated with a lower odds of impairment, whereas several other factors were no longer significantly correlated with global cognitive function (Table 3) . Results were similar in analyses excluding individuals with a history of stroke, excluding individuals whose primary language was not English, and after adjustment for quality-of-life scores. Using education-dependent 3MS cut points, the prevalence of global cognitive impairment was higher (26%). Correlates of global cognitive impairment were similar, except that the association between phase angle and global cognitive impairment was strengthened.
Impairment in Executive Function (Trails B)
In univariate analyses, older age, primary language other than English, lower educational attainment, stroke, higher comorbidity, and opioid use were significantly associated with a higher odds of impaired executive function (Table 4 ). In addition, higher weekly stdKt/V urea and narrower phase angle were associated with higher odds of impaired executive function, but the strength of the association diminished after casemix adjustment. Older age, primary language other than English, lower educational attainment, stroke, and use of H1-receptor antagonists and opioids were significantly correlated with impaired executive function after case-mix adjustment. Results were similar in analyses excluding individuals with a history of stroke except that the association with stdKt/V urea was slightly strengthened after case-mix adjustment (OR 1.06; 95% CI 1.00, 1.12 for each 0.1-unit increase in stdKt/V urea ). Findings were also similar when the analyses excluded individuals whose primary language was not English and after adjustment for quality-of-life scores.
Multivariable Analyses
In a parsimonious multivariable adjusted model, older age, primary language other than English, and lower educational attainment remained significantly associated with a higher odds of global cognitive impairment and impaired executive function (Table 5 ). Stroke and use of H1-receptor antagonists were associated with 2-to 3-fold higher odds of impaired executive function, but not with global cognitive impairment, whereas trial participation (nocturnal versus daily) was significantly associated only with lower odds of global cognitive impairment.
Discussion
We found that cognitive impairment was common in a large group of relatively young patients with ESRD participating in Table 1 . Subject clinical characteristics at baseline stratified by trial and randomization status Results are shown as mean Ϯ SD, median (IQR), or frequency (N, %), as appropriate. BUN, blood urea nitrogen; enPCR, normalized protein catabolic rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.
two clinical trials of more frequent hemodialysis and that impairment in executive function was almost twice as common as impairment in global cognition. In addition to several nonmodifiable factors, the use of H1-receptor antagonists and opioids were associated with cognitive impairment. We did not find a strong association between several other potentially modifiable factors associated with ESRD and dialysis therapy, such as urea clearance, proxies of dietary protein intake and other nutritional markers, hemodynamic measures, and anemia with global cognition and executive function after adjustment for case-mix factors. The prevalence of cognitive impairment in the FHN population was comparable to previous community-based studies of patients on dialysis after accounting for age differences. For example, in a study of 338 patients on hemodialysis over the age of 55, Murray et al. (2) It is notable that a sizeable fraction of subjects could not complete the Trails B even when the maximum time allowed for completion was doubled (Figure 2) , highlighting the profound impairment in executive function in this population, a finding suggested in previous studies (2, 12, 24) . This observation has several important implications. First, impaired executive function has been associated with poor judgment, adherence, and outcomes, including functional decline and mortality in nondemented elderly populations (25, 26) . Thus our findings suggest that cognitive evaluations that do not assess executive function may miss a substantial proportion of patients with cognitive impairment that may be clinically important. Second, the higher incidence of impaired executive function compared with global cognitive function and the relatively modest degree of overlap of these impairments suggests that there are multiple factors (and probably lesions) contributing to impaired cognition in patients with ESRD (11) . Brain imaging studies have demonstrated vascular disease lesions are commonly seen in patients with ESRD, even in the absence of clinical stroke (27, 28) . Studies aimed at localizing the ischemic regions of the brain in patients with ESRD may help explain the differing types of cognitive deficits.
Counter to our hypothesis, higher urea clearance, as reflected by the weekly stdKt/V urea , was associated with worse rather than better executive function. This finding appears not to be unique to this patient population (2) . Taken together, these associations would seem to predict a detrimental rather than beneficial effect of more intensive dialysis on cognitive function, a conclusion that is clearly different from that reached by early studies, when standards for urea removal were lower than current practice (7). We provide three possible explanations for this counterintuitive association. First, there may be a selection bias in which patients with greater cognitive impairment are dialyzed more intensively. Second, repeated rapid removal of solutes might have previously unappreciated cumulative detrimental effects on cognition. For example, there is evidence that the process of dialysis produces transient cognitive deficits (29) . Third, patients with a smaller ultrafiltration volume may be at independent risk for cognitive impairment. In support of this possibility, we found that narrower phase angle and lower serum albumin were associated with trends for higher odds of impaired executive function. Malnutrition may be a marker of inflammation, which has been associated with cognitive impairment and dementia in the general population (30) . Conversely, malnutrition may be a consequence rather than a cause of cognitive impairment.
In the FHN population, 13% to 25% of patients with ESRD were receiving CNS-active medications. Our findings suggest that these medications, especially H1-receptor antagonists and Note that global cognitive impairment was defined as a score Ͻ80 on the 3MS and impaired executive function was defined as a score Ն300 seconds on the Trails B test. (31, 32) . Given the association between H1-receptor antagonist use and impaired cognitive function, coupled with the lack of proven efficacy for uremic pruritus or other symptoms associated with ESRD or hemodialysis, these agents may be overutilized in patients with ESRD. Strengths of this study include the large ethnically and geographically diverse group of subjects, the use of two objective measures of cognitive function, and the standardized assessment of several ESRD-associated factors and treatment factors. However, several limitations should be noted. FHN subjects are similar to the U.S. ESRD population with respect to demographic characteristics, but they are likely to differ in other aspects that are not easily measured; thus, these results may not be generalizable to the larger population with ESRD. Our sample was large compared with previous studies; however, we had limited statistical power to detect associations that were modest in magnitude after multivariable adjustment. In addition, the narrow distribution range (e.g., hemoglobin) or low sensitivity (e.g., intradialytic hypotension) of some variables may have also limited our statistical power. We found less impairment in participants in the nocturnal study, possibly because of additional screening by home dialysis program staff before study entry. Because these analyses were cross-sectional, we could not determine whether the associations we found were causal. Longitudinal analyses of cognitive function in FHN subjects may provide additional insight into the factors associated with cognitive impairment and the extent to which it may be modifiable.
In summary, cognitive impairment, especially impaired executive function, is common among patients with ESRD participating in two clinical trials of more frequent hemodialysis schedules. However, with the exception of CNS-active medications, cognitive impairment is not associated in cross-sectional analysis with several modifiable ESRD-and dialysis-associated factors. The risks and benefits of certain CNS-active medications in patients with ESRD, especially H1-receptor antagonists, may deserve reassessment. 
